Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heidelberg Assay Panel and B-cell/antibody response to predict clinical effect of Octagam 5% in RR multiple sclerosis
2008-004579-22Phase 2Terminated
- Sponsor
- Octapharma
- Start
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Human normal immunoglobulin G in multiple sclerosis (MS), sponsored by Octapharma. Primary endpoint: Heidelberg Assay Panel correlations with clinical effect. Started Sep 2008; status: terminated.
02
Drugs
Human normal immunoglobulin G
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-004579-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004579-22.